Osaterone acetate
Progestin; Progestogen ester | |
Pharmacokinetic data | |
---|---|
Protein binding | Osaterone acetate: 90% 15β-Hydroxyosaterone acetate: 80%[1] (Both mainly to albumin)[1] |
Metabolism | Liver[1] |
Metabolites | 15β-Hydroxyosaterone acetate[1] |
Elimination half-life | Dogs: 80 hours to 197 ± 109 hours[1][2] |
Excretion | Bile: 60%[1] Urine: 25%[1] |
Identifiers | |
| |
JSmol) | |
| |
|
Osaterone acetate, sold under the brand name Ypozane, is a medication which is used in veterinary medicine in Europe in the treatment of enlarged prostate in dogs.[1][3][4] It is given by mouth.[1]
Osaterone acetate is an
Osaterone acetate was introduced for veterinary use in 2007.[5] It is marketed in Europe.[6][1]
Uses
Veterinary
Osaterone acetate is used in veterinary medicine in Europe in the treatment of benign prostatic hyperplasia (BPH) in dogs.[1][3][4] It has been found to produce remission of clinical symptoms of BPH in 83% of dogs for six months after a single one-week course of treatment,[7] and can be used long-term.[4]
Available forms
Osaterone acetate comes in the form of 1.875 mg, 3.75 mg, 7.5 mg, and 15 mg oral tablets for veterinary use.[1]
Side effects
Pharmacology
Pharmacodynamics
Osaterone acetate is a
Pharmacokinetics
The major active metabolite of osaterone acetate is 15β-hydroxyosaterone acetate.[1] Osaterone acetate has a long biological half-life of 80 hours to 197 ± 109 hours in dogs.[1][2]
Chemistry
Osaterone acetate, also known as 2-oxachloromadinone acetate, as well as 17α-acetoxy-6-chloro-2-oxa-6-dehydroprogesterone or 17α-acetoxy-6-chloro-2-oxapregna-4,6-diene-3,20-dione, is a
History
Osaterone acetate was introduced for veterinary use in Europe under the brand name Ypozane in 2007.[6][5][1]
Society and culture
Generic names
Osaterone acetate is the
Brand names
Osaterone acetate is marketed under the brand name Ypozane by Virbac.[6]
Availability
Osaterone acetate is available widely throughout Europe, including in Belgium, Finland, France, Germany, Italy, the Netherlands, Norway, Poland, Sweden, Switzerland, and the United Kingdom.[6]
Research
Osaterone acetate was also investigated in Japan in the treatment of prostate cancer and BPH in humans but was ultimately never marketed for such purposes.[3][10]
References
- ^ a b c d e f g h i j k l m n o p q r s t "Ypozane for Dogs" (PDF). European Medicines Agency.
- ^ ISBN 978-0-7020-2858-8.
- ^ ISBN 978-3-319-13278-5.
- ^ ISBN 978-1-4987-2850-8.
- ^ S2CID 257184365.
- ^ a b c d e f g h "Osaterone". Drugs.com.
- ISBN 978-0-323-24074-1.
- ^ ISBN 978-1-4557-4447-3.
- ^ ISBN 978-1-4377-0282-8.
- ISBN 978-1-60761-471-5.
Further reading
- Schröder FH, Radlmaier A (2009). "Steroidal Antiandrogens". Hormone Therapy in Breast and Prostate Cancer. Cancer Drug Discovery and Development. Humana Press. pp. 325–346. ISBN 978-1-60761-471-5.